The goal of this study is to develop an improved assay for rapid, reproducible, accurate, and cost-effective ERBB2 CN estimation, and to evaluate the relationship of a more accurate estimation of ERBB2 CN to the response to trastuzumab across a large breast cancer patient cohort. The gene discussed is ERBB2; the disease is breast cancer.